

We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

4,800

Open access books available

122,000

International authors and editors

135M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities



WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.

For more information visit www.intechopen.com



The Anti-Atherogenic Effects of Lycopene

Amany M. M. Basuny

Additional information is available at the end of the chapter

<http://dx.doi.org/10.5772/48134>

1. Introduction

Cardiovascular diseases (CVD) are one of the leading causes of death in world. Many epidemiological studies have concluded that a diet rich in fruits and vegetables reduces the incidence of heart disease in humans (Khachik *et al.*, 2002). Carotenoids are important photochemical those are considered to be responsible for the health protective effects of fruits and vegetables (Omoni & Aluko, 2005). The carotenoids are a group of over 600 fat soluble pigments that are responsible for the natural yellow, orange, and red colors of fruits and vegetables (Giovannucci, 2002). Lycopene is one of such carotenoids, and is the pigment principally responsible for the distinctive red color of ripe tomato (*Lycopersicon esculentum*) and tomato products (Shi, 2000). Several epidemiological studies have suggested that a high consumption of tomatoes and tomato products containing lycopene may protect against CVD (Wu *et al.*, 2003). These epidemiological leads have stimulated a number of animal model studies designed to test this hypothesis and to establish the beneficial effects of lycopene. Evidence from these studies suggests that lycopene has anti-atherogenic effects both in vitro and in vivo. The focus of this chapter is the anti-atherogenic effects of lycopene. This chapter will also highlight the chemical composition of lycopene, its sources and function, as well as potential impact an human health.

2. Sources and function of lycopene

Animals and humans do to not synthesize lycopene, and thus depend on dietary sources. Tomatoes and tomato products are the major dietary sources of lycopene. Other sources include watermelon, pink grapefruit, apricots, pink guava and papaya (Willis & Wians, 2003). Lycopene is the most abundant carotenoid in ripe tomatoes, comprising approximately 80-90% of the pigments present. The amount of lycopene in fresh tomatoes depends on the variety, maturity, and environmental conditions in which the fruit matures (Shi, 2000).

Source	Lycopene content (mg/100g wet basis)
Tomatoes fresh	0.72 – 20
Tomato juice	5.00 – 11.60
Tomato sauce	6.20
Tomato paste	5.40 – 15.00
Tomato soup	7.99
Ketchup	9.90 – 13.44
Pizza sauce	12.71
Watermelon	2.30 – 7.20
Pink guava	5.23 – 5.50
Pink grapefruit	0.35 – 3.36
Papaya	0.11 – 5.30
Carrot	0.65 – 0.78
Pumpkin	0.38 – 0.46
Sweet potato	0.02 – 0.11
Apricot	0.01- 0..05

Table 1. shows the lycopene content of tomatoes, some commonly consumed tomato products and other lycopene containing fruits and vegetables.

Lycopene is also widely distributed in the human body. It is one of the major carotenoids found in the human serum (between 21 and 43% of total carotenoids) with plasma levels ranging from 0.22 to 1.06 nmol/ml (Cohen, 2002). It is also found in various tissues throughout the body such as the liver, kidney, adrenal glands, tests, ovaries and the prostate gland (Basu & Imrhan, 2006). Unlike other carotenoids like α - and β -carotene, lycopene lacks the β :ionone ring structure common to other carotenoids (Agarwal & Rao, 2000). Although it lacks provitamine activity, lycopene is known to be a potent antioxidant (Livny *et al.*, 2002). Reactive oxygen (ROS) species have been implicated in playing a major role in the causation and progression of several chronic diseases. These ROS are highly reactive oxidant molecules that are generated endogenously through regular metabolic activity. They react with cellular components, causing oxidative damage to such critical cellular biomolecules as lipids, proteins and DNA. Antioxidants are protective agents that inactivate ROS and therefore, significantly delay or prevent oxidative damage associated with chronic disease risk. Lycopene is one of the most potent antioxidants among the dietary carotenoids and may help lower the risk of chronic diseases including cancer and heart disease.

3. Chemical composition of lycopene

Lycopene is a lipophilic, 40-carbon atom highly unsaturated, straight chain hydrocarbon containing 11 conjugated and 2 non-conjugated double bonds. The all-trans isomer of lycopene is the most predominant isomer in fresh tomatoes and is the most thermodynamically stable form (figure 1). The many conjugated double bonds of lycopene make it a potentially powerful antioxidant, a characteristic believed to be responsible for its beneficial effects. The antioxidant

activity of lycopene is high light by its singlet oxygen-quenching property and its ability to trap peroxy radicals. This singlet quenching ability of lycopene is twice as high as that of β -carotene and 10 times higher than that of α -tocopherol and butylated hydroxyl toluene.




Figure 1. All-*trans* Lycopene.

As a result of the 11 conjugated carbon-carbon double bonds in its backbone, lycopene can theoretically assume 211 or 2048 geometrical configurations (Omani & Aluko, 2005).

However, it is now known that the biosynthesis in plants leads to the all-*trans*-form, and this is independent of its thermodynamic stability. In human plasma, lycopene is an isomeric mixture, containing at least 60% of the total lycopene as *cis*- isomers (Kim *et al.*, 2012).

All-*trans*, 5-*cis*, 9-*cis*, 13-*cis*, and 15-*cis* are the most commonly identified isomeric forms of lycopene with the stability sequence being 5-*cis*>all-*trans*>9-*cis*>13-*cis*>15-*cis*>7-*cis*>11-*cis*, (Agarwal & Rao, 2000) so that the 5-*cis*-form is thermodynamically more stable than the all-*trans*-isomer. Whereas a large number of geometrical isomers are theoretically possible for all-*trans* lycopene, according to only certain ethylenic groups of a lycopene molecule can participate in *cis-trans* isomerization because of steric hindrance. In fact, only about 72 lycopene *cis* isomers are structurally favorable. Figure 2 illustrates the structural distinctions of the predominant lycopene geometrical isomers.




Figure 2. Geometrical isomers of lycopene

4. Mechanisms action of lycopene

A cellular and molecular study have shown lycopene to be one of the most potent antioxidants and has been suggested to prevent atherogenesis by protecting critical biomolecules such as DNA, proteins, lipids and low density lipoproteins (Pool-zobel *et al.*, 1997). Lycopene, because of its high number of conjugated double bonds, exhibits higher singlet oxygen quenching ability compared to β -carotene or α -tocopherol (Di-Mascio *et al.*, 1989). Cis lycopene has been shown to predominate in both benign and malignant prostate tissues, suggesting a possible beneficial effect of high cis-isomer concentrations, and also the involvement of tissue isomerases in vivo isomerization from all trans to cis form (Clinton *et al.*, 1996). Where as Levin *et al.*, (1997) have shown that 9- cis- β -carotene is a better antioxidant than its all-trans counterpart, no such mechanistic data have been reported in case of individual lycopene isomers. Handley *et al.*, (2003) reported a significant increase in 5-cis lycopene concentrations following a 1- week lycopene-restricted diet, and a subsequent reduction in 5-cis, and a concomitant increase in cis- β , cis-D and cis-E lycopene isomers during the 15-day dietary intervention with tomato products in healthy individuals. Although this study reported a decrease in LDL oxidizability due to the intervention with tomato lycopene, the individual antioxidant role of lycopene isomers and their inter conversions remain unclear. At a physiological concentration of 0.3 $\mu\text{mol/l}$, lycopene has been shown to inhibit growth of non-neoplastic human prostate epithelial cells in vitro, through cell cycle arrest which may be of significant implications in preventing benign prostate hyperplasia, a risk factor for prostate cancer (Obermuller-Jevic *et al.*, 2003). Lycopene has also been shown to significantly reduce LNCaP human prostate cancer cell survival in a dose-dependent manner, and this anti-neoplastic action may be explained by increased DNA damage at high lycopene concentrations ($> 5\mu\text{m}$), whereas lower levels of lycopene reduced malondialdehyde formation, with no effects on DNA (Hwang & Bowen, 2005). Physiologically attainable concentrations of lycopene have been shown to induce mitochondrial apoptosis in LNCaP human prostate cancer cells, although no effects were observed on cellular proliferation or necrosis (Hantz *et al.*, 2005). Lycopene has also been shown to interfere in lipid metabolism, lipid oxidation and corresponding development of atherosclerosis. Lycopene treatment has been shown to cause a 37% suppression of cellular cholesterol synthesis in J-774A.1 macrophage cell line, and augment the activity of macrophage LDL receptors (Fuhrman *et al.*, 1997). Oxidized LDLs are highly atherogenic as they stimulate cholesterol accumulation and foam cell formation, initiating the fatty streaks of atherosclerosis (Libby, 2006). LDL susceptibility to oxidative modifications is decrease by an acyl analog of platelet-activating (PAF), acyl-PAF, which experts its beneficial role during the initiation and progression of atherosclerosis. Purified lycopene in association with α -tocopherol or tomato lipophilic extracts has been shown to enhance acyl-PAF biosynthesis in endothelial cells during oxidative stress (Balestrieri *et al.*, 2004). Fuhrman *et al.*, (2000) further reported comparative data in which tomato oleoresin exhibited superior capacity to inhibit in vitro LDL oxidation in comparison with pure lycopene by up to fivefold. A combination of purified lycopene (5 $\mu\text{mol/l}$) with α -toopherol in the concentration range of 1-10 $\mu\text{mol/l}$ resulted in a significant greater inhibition of in vitro LDL oxidation, than the

expected additive individual inhibitions. In this study, purified lycopene was also shown to act synergistically with other natural antioxidants like the flavonoid glabridin, the phenolics rosmarinic acid and carnosic acid, and garlic acid in inhibiting LDL oxidation *in vitro*. These observations suggested a superior antiatherogenic characteristic of tomato oleoresin over pure lycopene. The combination of lycopene with other natural antioxidants, as in tomatoes, may be more potent in inhibiting lipid peroxidation, than lycopene *per se*. The antiatherogenic effects of lycopene are generally believed to be due to its antioxidant properties. Dietary lycopene increases blood and tissue lycopene levels and acting as an antioxidant, lycopene traps reactive oxygen species and reduce the oxidative damage to lipids (lipoproteins and membrane lipids), proteins including important enzymes, and DNA, thereby lowering oxidative stress. This reduced oxidative stress then leads to a reduced risk for chronic diseases associated with oxidative stress such as cardiovascular disease (Omani & Aluko 2005). Alternatively, some non-oxidative mechanisms may be responsible for the beneficial effects of lycopene. The increased lycopene status in the body may regulate gene functions, improve intercellular communication, modulate hormone and immune response, or regulate metabolism, thus lowering the risk for chronic disease (Agarwal & Rao, 2000). A possible mechanism speculated for the protective role of lycopene in heart disease is via the inhibition of cellular HMGCoA reductase, the rate-limiting enzyme in cholesterol synthesis (Fuhrman *et al.*, 1997).

5. Lycopene stability

Being acyclic, lycopene possesses symmetrical planarity and has no vitamin A activity, and as a highly conjugated polyene, it is particularly susceptible to oxidative degradation. Physical and chemical factors known to degrade other carotenoids, including elevated temperature, exposure to light, oxygen, extremes in pH, and molecules with active surfaces that can destabilize the double bonds, apply to lycopene as well (Rao *et al.*, 2003).

In a study to determine the photoprotective potential of dietary antioxidants including lycopene carried out by Handley *et al.*, (2003) carotenoids were prepared in special nanoparticle formulations together with vitamin C and/or vitamin E. The presence of vitamin E in the formulation further increased the stability and cellular uptake of lycopene, which suggests that vitamin E in the nanoparticle, protects lycopene against oxidative transformation. Their findings suggest that lycopene stability may be improved by nanoparticle formulation and incorporation of vitamin E in the lycopene formulation.

Badimon *et al.*, 2010 studied the stability of lycopene during heating and illumination. They carried out various pretreatment steps to the all-trans lycopene standard, which included; dissolving the lycopene standard into hexane and evaporating to dryness under nitrogen in vials, after which a thin film formed at the bottom surface. The resulting lycopene was heated at 50, 100, and 150°C or illuminated at a distance of 30 cm with illumination intensity in the range of 2000–3000 lux (25°C) for varied lengths of time (up to 100 hours for heating and 5 days for illumination). After analysis, the degradation of total lycopene (all-trans plus *cis* forms) during heating or illumination was found to fit a first-order model. At 50°C, the

isomerization dominated in the first 9 hours; however, degradation was favored afterwards. At 100 and 150°C, the degradation proceeded faster than the isomerization, whereas, during illumination, isomerization was the main reaction. The degradation rate constant (min^{-1}) of lycopene was found to rise with increasing temperature with an activation energy calculated as 61.0 kJ/mol.

The stability of crystalline lycopene was determined under various temperature conditions (5, 25, and 35°C) while stored in airtight containers, sealed under inert gas, and protected from light. After 30 months of storage, crystalline lycopene remained stable when stored under the recommended conditions (Barros *et al.*, 2011).

Lycopene (synthetically prepared by the Wittig reaction) 5% TG (Tablet Grade) and lycopene 10% WS (Water Soluble) beadlet formulations tested for over 24 months of storage, and Lycopene 10% FS (Fluid Suspension) liquid formulation tested for over 12 months of storage under various temperature conditions (5 and 25°C), were all found to be stable. (25) For the 10% WS lycopene beadlet formulations, an important market application form, stability with respect to oxidation under ambient light conditions and room temperature for 12 months in beverages was found to be 93% of the initial content of the beverage lycopene (Pool-zobel *et al.*, 1997).

6. Dietary intake of lycopene

The human body is unable to synthesize carotenoids, which qualifies diet as the only source of these components in blood and tissues. At least 85% of our dietary lycopene comes from tomato fruit and tomato-based products, the remainder being obtained from other fruits such as watermelon, pink grapefruit, guava, and papaya, Tomatoes are an integral part of the human diet and are commonly consumed in fresh form or in processed form such as tomato juice, paste, puree, ketchup, soup, and sauce. Kim *et al.*, (2012) used a tomato products consumption frequency questionnaire to estimate the average daily consumption of different tomato products in the Canadian population.

Di-Mascio *et al.*, (1989) estimated that 50% of the dietary lycopene was obtained from fresh tomatoes, while the average daily intake of lycopene was estimated to be 25 mg in the Canadian population. In a British study conducted with elderly females, the daily consumption of lycopene-rich food, such as tomatoes and baked beans in tomato sauce (measured by weight of foods eaten), was equivalent to a daily lycopene intake of 1.03 mg per person (Omani & Aluko, 2005) developed a database from which the carotenoid intake of the German population, stratified by sex and age, was evaluated on the basis of the German National Food Consumption Survey (NVS). The mean total carotenoid intake amounted to 5.33 mg/day. The average intake of lycopene was 1.28 mg/day with tomatoes and tomato products providing most of the lycopene.

A study presenting data on dietary intake of specific carotenoids in The Netherlands, based on a food composition database for carotenoids, was done by Furrman *et al.*, (1997). Regularly eaten vegetables, the main dietary source of carotenoids, were sampled comprehensively and

analyzed with modern analytic methods. The database was complemented with data from literature and information from food manufacturers. Intake of carotenoids was calculated for participants of the Dutch Cohort Study on diet and cancer, aged 55 to 69 in 1986, and the mean intake of lycopene was 1.0 mg/day for men and 1.3 mg/day for women.

6.1. Bioavailability of lycopene

Although 90% of the lycopene in dietary sources is found in the linear, all-trans conformation, human tissues (Particularly liver, adrenal, adipose tissue, testes and prostate) contain mainly cis-isomers. Holloway *et al.*, (2002) reported that a dietary supplementation of tomato puree for 2 weeks in healthy volunteers led to a completely different isomer pattern of plasma lycopene in these volunteers, versus those present in tomato puree. 5-cis, 13-cis and 9-cis lycopene isomers, not detected in tomato puree, were predominant in the serum (Holloway *et al.*, 2000). Analysis of plasma lycopene in male participants in the health professionals follow-up study revealed 12 distinct cis-isomers and the total cis-lycopene contributed about 60-80% of total lycopene concentrations (Wu *et al.*, 2003). Studies conducted with lymph cannulated ferrets have shown better absorption of cis-isomers and their subsequent enrichment in tissues (Boileau *et al.*, 1999). Physicochemical studies also suggest that cis-isomer geometry accounts for more efficient incorporation of lycopene into mixed micelles in the lumen of the intestine and into chylomicrons by the enterocyte. Cis-isomers are also preferentially incorporated by the liver into very low-density lipoprotein (VLDL) and get secreted into the blood (Britton, 1995). Research has shown convincing evidence regarding the isomerization of all trans-lycopene to cis-isomers, under acidic conditions of the gastric juice. Incubation of lycopene derived from capsules with simulated gastric juice for 1-min shown a 40% cis-lycopene content, whereas the levels did not exceed 20% even after 3h incubation with water as a control. However, when tomato puree was incubated for 3h with simulated gastric juice, the cis-lycopene content was only 18% versus 10% on incubation with water. Thus, gastric pH and food matrix influence isomerization and subsequent absorption and increased bioavailability of cis-lycopene (Re *et al.*, 2001).

The process of cooking which releases lycopene from the matrix into the lipid phase of the meal increases its bioavailability, and tomato paste and tomato puree are more bioavailable sources of lycopene than raw tomatoes (Gartner *et al.*, 1997 & Porrini *et al.*, 1998). Factors such as certain fibers, fat substituents, plant sterols and cholesterol-lowering drugs can interfere with the incorporation of lycopene into micelles, thus lowering its absorption (Boileau *et al.*, 2002). Several clinical trials have also shown the bioavailability of lycopene from processed tomato products (Table 2). Agarwal and Rao (1998), reported a significant increase in serum lycopene levels following a 1-week daily, consumption of spaghetti sauce (39mg of lycopene), tomato juice (50mg of lycopene) or tomato oleoresin (75 or 150 mg of lycopene), in comparison with the placebo, in healthy human volunteers. There was also indication that the lycopene levels increased in a dose-dependent manner in the case of tomato sauce and tomato oleoresin. Reboul *et al.*, (2005) further demonstrated that enrichment of tomato paste with 6% tomato peel increases lycopene bioavailability in men, thereby suggesting the beneficial effects of peel enrichment, which are usually eliminated

during tomato processing. Richelle *et al.*, (2002) compared the bioavailability of lycopene from tomato paste and from lactolycopene formulation (Lycopene from tomato oleoresin embedded in a whey protein matrix), and reported similar bioavailability of lycopene from the two sources in healthy subjects. Dietary fat has been shown to promote lycopene absorption, principally via stimulating bile production for the formation of bile acid micelles. Consumption of tomato products with olive oil or sunflower oil has been shown to produce an identical bioavailability of lycopene, although plasma antioxidant activity improved with olive oil consumption, suggesting a favorable impact of monounsaturated fatty acids on lycopene absorption and its antioxidant mechanism (Lee *et al.*, 2000). In an interesting study Unlu *et al.*, (2005) reported the role of avocado lipids in enhancing lycopene absorption. In this study, in healthy, nonpregnant, nonsmoking adults, the addition of avocado oil (12 or 24g) to salsa (300g) enhanced lycopene absorption, resulting in 4.4 times the mean area under the concentration-versus-time curve after intake of avocado-free salsa. This study demonstrates the favorable impact of avocado consumption on lycopene absorption and has been attributed to the fatty acid distribution of avocados (66.00% oleic acid), which may facilitate the formation of chylomicrons. In a comparative study by Hoppe *et al.*, (2003), both synthetic and tomato –based lycopene supplementation showed similar significant increases of serum total lycopene above baseline whereas no significant changes were found in the placebo group. In an attempt to study lycopene metabolism, Diwadkar-Navsariwala *et al.*, (2003) developed a physiological pharmacokinetic model to describe the disposition of lycopene, administered as a tomato beverage formulation at five graded doses (10, 30, 60, 90, or 120 mg) in healthy men. Blood was collected before dose administration and at scheduled study intervals until 672h. The overall results of this study showed that independent of dose, 80% of the subjects absorbed less than 6mg of lycopene, suggesting a possible saturation of absorptive mechanisms. This may have important implications for planning clinical trials with pharmacological doses of lycopene in the control and prevention of chronic disease, if absorption saturation occurs at normally consumed levels of dietary lycopene.

6.2. The anti-atherogenic effects of lycopene

In a previous study (Basuny *et al.*, 2006 and 2009) was to study the effect of tomato lycopene on hypercholesterolemia. Lycopene of tomato wastes was extracted and determination. The level of tomato lycopene was 145.50ppm. An aliquots of the concentrated tomato lycopene, represent 100, 200, 400 and 800ppm; grade lycopene (200ppm) and butylated hydroxyl toluene (BHT, 200ppm) were investigated by 1,1-diphenyl-2-picrylhydrazyl (DPPH) free radical scavenging method. These compounds were administered to rats fed on hypercholesterolemic diet daily from 10 weeks by stomach tube. Serum lipid contents (total lipids, total cholesterol, high density lipoprotein cholesterol and low density lipoprotein cholesterol), oxidative biomarkers (glutathione peroxidase and malonaldehyde), the liver (aspartate aminotransferase, alanine aminotranseferase and alkaline phosphatase activities) and kidney (uric acid, urea and creatinine) function testes were measured to assess the safety limits of the lycopene in tomato wastes. The data of the aforementioned measurements indicated that the administration of tomato lycopene did not cause any

changes in liver and kidney functions. On the contrary, rats fed on hypercholesterolemic diet induced significant increases in the enzymes activities and the serum levels of total lipids, total cholesterol and low and high density lipoproteins cholesterol and decreased levels of the glutathione peroxidase and malonaldehyde. In conclusion, presently available data from epidemiological and a number of animal studies have provided evidence to suggest that lycopene, the naturally present carotenoid in tomatoes and other fruits and vegetables, possesses anti-atherogenic effects. However, there is a need for more human dietary intervention studies in order to better understand the role of lycopene in human health.

Scientific evidence indicates that oxidation of low density lipoprotein (LDL), which carry cholesterol in the blood stream plays an important role in the development of atherosclerosis, the underlying disorder leading to heart attacks and ischemic strokes (Rao, 2002). Several studies indicate that consuming the antioxidant lycopene that is contained in tomatoes and tomato lycopene products can reduce the risk of cardiovascular diseases (CVD). Available evidence from the Kuopio Ischaemic Heart Disease Risk Factor (KIHD) study suggests that the thickness of the innermost wall of blood vessels and the risk of myocardial infarction reduced in persons with higher serum and adipose tissue concentrations of lycopene (Rissanen *et al.*, 2003). This finding suggests that the serum lycopene concentration may play a role in the early stages of atherosclerosis. A thick artery wall is a sign of early atherosclerosis, and increased thickness of the intima media has been shown to predict coronary events. Similarly, the relationship between plasma lycopene concentration and intima-media thickness of the common carotid artery wall (CCA-IMT) was investigated in 520 middle-aged men and women 45-69 years as parts of the Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) study (Rissanen *et al.*, 2000). Low levels of plasma lycopene were associated with a 17.80% increment in CCA-IMT in men, while there was no significant difference among women. These findings also suggest that low plasma lycopene concentrations are associated with early atherosclerosis, evidenced by increased CCA-IMT in middle-aged men.

Findings from the Rotterdam Study (Klipstein-Grobusch *et al.*, 2000) showed modest inverse associations between levels of serum lycopene and atherosclerosis, assessed by the presence of calcified plaques in the abdominal aorta. Study population comprised of 108 cases of aortic atherosclerosis and 109 controls aged 55 years and over. The association between serum lycopene levels and atherosclerosis was most pronounced among subjects who were current and former smokers. No association with risk of aortic calcification for the serum carotenoids α -carotene, β -carotene, lutein and zeaxanthin was observed. These results suggest that lycopene may play a protective role in the development of atherosclerosis. Results from the European Study of Antioxidant, Myocardial Infarction, and Cancer of the breast (the EURAMIC study) also show that men with the highest concentration of lycopene in their adipose tissue biopsy had a 48% reduction in risk of myocardial infarction compared with men with the lowest adipose lycopene concentrations (Kohlmeir *et al.*, 1997). An increase in LDL oxidation is known to be associated with an increased risk of atherosclerosis and coronary heart disease (Parthasarathy, 1998). Agarwal and Rao (1998) investigated the effect of dietary supplementation of lycopene on LDL oxidation in 19 healthy human subjects. Dietary lycopene was provided using tomato juice, spaghetti sauce and tomato oleoresin for a

period of 1 week each. Blood samples were collected at the end of each treatment, and TBARS and conjugated dienes were measured to estimate LDL oxidation. In addition to significantly increasing serum lycopene levels by a least twofold, lycopene supplementation significantly reduced serum lipid peroxidation and LDL oxidation. The average decrease of LDL –TBARS and LDL-conjugated diene for the tomato products treatment over placebo was 25 and 13%, respectively. These results suggest significance for lycopene in decreasing risk for coronary heart disease. Results from the ongoing Women's Health Study (WHS) showed that women with the highest intake of tomato-based foods rich in lycopene had a reduced risk for CVD compared to women with a low intake of those foods (Sesso *et al.*, 2003). Results showed that women who consumed seven servings or more of tomato based foods like tomato sauce and pizza each week had a nearly 30% risk reduction in total CVD compared to the group with intakes of less than one serving per week. The researchers also found out that women who ate more than 10 servings per week had an even more pronounced reduction in risk (65%) for specific CVD outcomes such as heart attack or stroke. Though not statistically significant, the strongest association of dietary lycopene with CVD protection was seen among women with a median dietary lycopene intake of 20.20 mg/day, who had a 33% reduction in risk of the disease when compared with women with the lowest dietary lycopene intake (3.3 mg/day).

Lycopene has also been shown to have a hypercholesterolemic effect both in vivo and in vitro. In a small dietary supplementation study, six healthy male subjects were fed 60 mg/day lycopene for 3 months. At the end of the treatment period, a significant 14% reduction in plasma LDL cholesterol levels was observed in vivo with no effect on HDL cholesterol concentration (Fuhrman *et al.*, 1997) & Lorenz *et al.*, 2012).

6.3. Safety of lycopene

The safety issue for carotenoids attracted much attention after the publication of the β -carotene supplementation trials, which yielded negative results. It is interesting that in thus studies an increased risk for lung cancer was related to a 12- and 16 fold increase in β -carotene plasma levels due to supplementation. β -carotene plasma levels increased from 0.32 μ ml before supplementation up to 3.90 and 5.90 μ m, respectively. Rao *et al.*, (2003), which showed no effect for β -carotene supplementation, only a 5-fold increase in the carotenoid serum level was achieved. Interestingly, the only study with positive results after supplementation with β -carotene was achieved in linxian, a chinese community with very low carotenoid levels (0.11 μ m) before the intervention (Jonker *et al.*, 2003). Although supplementation caused an 11-fold increase in β -carotene level, the final concentration of β -carotene reached was a relatively low 1.5 μ m. Interestingly, reviewing many studies which measured serum levels of β -carotene and lycopene after supplementation suggests that β -carotene serum levels are significantly higher than those found for lycopene. Serum levels reached for β -carotene are around 3 μ m and may exceed 5 μ m after supplementation; on the other hand lycopene levels above 1.2 μ m are rarely seen even after long-term application. Moreover, the serum level achieved for lycopene was not directly correlated to the amount of the supplementation carotenoid (Nahum *et al.*, 2001). For example, supplemented as high as 75 mg/day did not increase lycopene serum levels

more than 1 μ m (Agarwal & Rao 1998). In conclusion, by some unknown mechanism, lycopene plasma levels after supplementation remain relatively low, which may provide a safety value.

6.4. Lycopene relationship with other micronutrients

When reviewing data related to the chemoprevention of various diseases, it became evident that the use of a single carotenoid, or any other micronutrient which has been successful in vitro and animal models, does not prove as favorable in human intervention studies. That is, there is no magic bullet. In fact, accumulating evidence suggests that a concerted, synergistic action of various micronutrients is, more likely to be the basis of the disease-prevention activity of a diet rich in vegetables and fruits. Indeed, the sources of lycopene used in most of the human studies reviewed there were either prepared tomato products or tomato extracts containing lycopene and other tomato micronutrients and carotenoids in various proportions. Pure lycopene has not been tested as a single in human prevention studies. On the other hand, many studies showing the beneficial effect of lycopene in alleviating chronic conditions have been conducted in which the subjects were provided with tomato-based foods, or tomato extracts, but not with the pure compound. For example, the oleoresin preparation used in many of these studies also contained other tomato carotenoids such as phytoene, phytofluene and β -carotene (Amir *et al.*, 1999; Pastori *et al.*, 1998 & Stahl *et al.*, 1998). In a recent study (Bioleau *et al.*, 2003) that compared the potency of freeze-dried whole tomatoes (tomato powder) or pure lycopene in a rat model of prostate cancer. Rats were treated with the carcinogen (N-methyl-N-nitrosourea) combined with androgens to stimulate prostate carcinogenesis, and the ability of these two preparations containing lycopene to enhance survival was compared. Mortality with prostate cancer was lower by 25 % (p= 0.09) for rats fed the tomato powder diet than for rats fed control feed. Prostate cancer mortality of rats fed our lycopene was similar to that of the control group. The authors concluded that consumption of tomato powder but not pure lycopene inhibited prostate carcinogenesis, suggesting that tomato products contain other compounds, besides lycopene, that modify prostate carcinogenesis.

6.5. Epidemiologic studies: lycopene and cardiovascular diseases

Epidemiological observations also report an inverse association between plasma or tissue lycopene levels and the incidence of cardiovascular diseases. In the Kuopio Ischemic Heart Disease Risk Factor Study, lower levels of plasma lycopene were seen in men who had a coronary event compared with men who did not. In addition, a higher concentration of serum lycopene was inversely correlated with a decrease in the mean and maximal intima-mediated thickness of the common carotid artery (CCA-IMT) with low lycopene, resulting in an 18% increase in CCA-IMT (Rissanen *et al.*, 2003). The European Multicenter Case-Control Study on antioxidants, Myocardial Infarction and Breast Cancer Study (EURAMIC Study) reported that a higher lycopene concentration was independently protective against cardiovascular diseases (Basu & Imrhan 2006). The Women's Health Study further revealed that a decreased risk for developing cardiovascular diseases was more strongly associated with higher tomato intake than with lycopene intake (Sesso *et al.*, 2003). Processed tomato products definitely provide a bioavailability source of lycopene and have a positive correlation with plasma and tissue

lycopene levels. However, these studies do not suggest a role of lycopene *per se*, in reducing the risks for cardiovascular diseases, as plasma level of lycopene, in epidemiologic studies, only reflects the consumption of tomato and tomato products.

7. Conclusion

Thus, it can be concluded that moderate amounts of whole food-based supplementation (2–4 servings) of tomato soup, tomato puree, tomato paste, tomato juice or other tomato beverages, consumed with dietary fats, such as olive oil or avocados, leads to increases in plasma carotenoids, particularly lycopene. The recommended daily intake of lycopene has been set at 35 mg that can be obtained by consuming two glasses of tomato juice or through a combination of tomato products (Rao and Agarwal, 2000). These foods may have both chemopreventive as well as chemotherapeutic values as outlined in Figure 3. In the light of recent clinical trials, a combination of naturally occurring carotenoids, including lycopene, in food sources and supplements, is a better approach to disease prevention and therapy, versus a single nutrient. Lycopene has shown distinct antioxidant and anticarcinogenic effects at cellular levels, and definitely contributes to the health benefits of consumption of tomato products. However, until further research establishes significant health benefits of lycopene supplementation *per se*, in humans, the conclusion may be drawn that consumption of naturally occurring carotenoid-rich fruits and vegetables, particularly processed tomato products containing lycopene, should be encouraged, with positive implications in health and disease.




Figure 3. Summary of mechanisms of action of tomato products or tomato oleoresin supplementation, containing lycopene, in health and disease.

		Type and duration of lycopene supplementation	Effects on biomarkers of oxidative stress/ carcinogenesis	
Agarwal and Rao (1998)	19 healthy subjects (mean age 29 years, BMI 2472.8 kg/m ²)	0 mg lycopene (placebo), 39 mg lycopene (spaghetti sauce), 50 mg lycopene (tomato juice), or 75 mg lycopene (tomato oleoresin) per day for 1 week	25% decrease in LDL-TBARS 13% decrease in LDL-CD for all groups versus placebo (P<0.05)	Increase at 7 days in all groups versus placebo (P<0.05)
Riso et al. (1999)	10 healthy subjects (mean age 23.171.1 years, BMI 20.571.5 kg/m ²)	16.5 mg lycopene (60 g tomato puree), per day for 21 days	38% decrease in DNA damage in lymphocytes (P<0.05)	Increase at 21 days versus baseline (P<0.001)
Bub et al. (2000)	23 healthy volunteers (mean age 3474 years, BMI 2372 kg/m ²)	40 mg lycopene (330 ml tomato juice) for 2 weeks	12% decrease in plasma TBARS 18% increase in LDL lag time (P<0.05) no effects on water-soluble antioxidants, FRAP, glutathione peroxidase and reductase activities (P<0.05)	Increase at 2 weeks versus baseline (P<0.05)
Chopra et al. (2000)	34 healthy females (mean age 37.578.5 years, BMI 2473.5 kg/m ²)	440 mg lycopene (200 g tomato puree þ 100 g watermelon) per day for 7 days	Significant decrease in LDL oxidizability in nonsmokers (P<0.05); no effects in smokers (P<0.05)	Increase at 7 days versus baseline (P<0.05)
Porrini and Riso (2000)	9 healthy subjects (mean age 25.472.2years, BMI 20.371.5 kg/m ²)	7 mg lycopene (25 g tomato puree), per day for 14 days	50% decrease in DNA damage in lymphocytes (P<0.05)	Increase at 14 days versus baseline (P<0.001)
Upritchard et al. (2000)	15 well-controlled type II diabetics (mean age 6378years, BMI30.977 kg/m ²)	Tomato juice (500 ml) per day or placebo for 4 weeks	Decreased LDL oxidizability versus baseline (P<0.001)	Increase at 4 weeks versus baseline (P<0.001)
Hininger et al. (2001)	175 healthy volunteers (mean age 33.571 years, BMI-24.370.5 kg/m ²)	15 mg lycopene (natural tomato extract) or placebo per day for 12 weeks	No effects on LDL oxidation, reduced glutathione, protein SH groups and antioxidant metalloenzyme activities (P<0.05)	Increase at 12 weeks versus baseline (P<0.05)
Chen et al. (2001)	32 patients with localized prostate adenocarcinoma (mean age 63.776.1 years, BMI 28.074.9 kg/m ²)	30 mg lycopene (200 g spaghetti sauce) per day for 3 weeks before surgery or a reference group with no supplementation	Decreased leukocyte and prostate tissue oxidative DNA damage; decreased serum PSA levels (P<0.05)	Increase at 3 weeks versus baseline (P<0.001)
Kucuk et al. (2001)	26 patients with newly diagnosed, clinically localized prostate cancer (mean age 62.1571.85 years, BMI not reported)	15 mg lycopene (Lyc-O-Mato capsules) twice daily or no supplementation for 3 weeks before surgery	Decreased tumor growth in the intervention group versus control(P<0.05); decreased plasma PSA levels and increased expression of connexin43 in prostate tissue in the intervention group versus control (P<0.05);decreased plasma IGF-1 levels in intervention and control groups(P<0.05)	No effects at 3 weeks versus baseline (P<0.05)

		Type and duration of lycopene supplementation	Effects on biomarkers of oxidative stress/ carcinogenesis	
Porrini et al. (2002)	9 healthy subjects (mean age 25.272.2 years, BMI 20.271.6 kg/m ²)	7 mg lycopene (25 g tomato puree) with 150 g of spinach and 10 g of olive oil per day for 3 weeks	Decreased DNA oxidative damage (P<0.05)	Not reported

Table 2. Summary of clinical trials investigating the effects of supplementation of tomato products, tomato oleoresin or purified lycopene on biomarkers of oxidative stress and Carcinogenesis

Author details

Amany M. M. Basuny

Department of Fats & Oils, Food Technology Research Institute, Agriculture Research Centre, Giza, Egypt

8. References

- Agarwal, A. & Rao, A. (1998): Tomato lycopene and low density lipoprotein oxidation: a human dietary intervention study. *Lipids*, 33: 981-984.
- Agrawal, S. & Rao, V. (2000): Tomato lycopene and its role in human health and chronic diseases. *Canadian Medical Association Journal*, 163: 739-744.
- Amir, H.; Karas, M. & Giat, J. (1999): Lycopene 1, 25 di-hydroxy vitamin-D3 cooperate in the inhibition of cell cycle progression and induction of differentiation in HL-60 leukemic cells. *Nutrition Cancer*, 33: 105-112.
- Badiman, L.; Vilahur, G. & Padro, T. (2010): Nutraceuticals and atherosclerosis: Human trials. *Cardiovascular Therapeutics*, 28: 202-215.
- Barros, L.; Carbrita, L.; Boas, M.; Carvaiho, A. & Ferreira, I. (2011): Chemical, biochemical and electrochemical assays to evaluate phytochemicals and antioxidant activity of wild plants. *Food Chemistry*, 127: 1600-1608.
- Basu, A. & Imrhan, V. (2006): Tomato versus lycopene in oxidative stress and carcinogenesis: conclusions from clinical trials. *European Journal OF Clinical Nutrition*, 1-9.
- Basuny, A. M.; Mostafat, D. M. & Azouz, A. (2006): Supplementation of polyunsaturated oils with lycopene as natural antioxidant and antipolymerization during heating process. *Minia Journal of Agricultural Research and Development*, 26: 449-469.
- Basuny, A. M.; Gaafar, A. M. & Arafat, S. M. (2009): Tomato lycopene is a natural antioxidant and can alleviate hypercholesterolemia. *African Journal of Biotechnology*, 23: 6627-6633.
- Boileau, T. W.; Liao, Z.; Kim, S.; Lemeshow, S.; Erdman, J. & Clinton, S. (2003): Prostate carcinogenesis in N-methyl-N-nitrosourea (NMW)-testosterone-treated rats fed tomato powder, lycopene, or energy-restricted diets. *J Natl. Cancer Inst.* 95: 1578-1586.

- Boileau AC, Merchen NR, Wasson K, Atkinson CA, Erdman JW (1999). cis-Lycopene is more bioavailable than trans-lycopene in vitro and in vivo in lymph-cannulated ferrets. *J Nutr* 129, 1176–1181.
- Boileau TWM, Boileau AC, Erdman JW (2002). Bioavailability of alltrans and cis-isomers of lycopene. *Exp Biol Med* 227, 914–919.
- Britton, G. (1995): Structure and properties of carotenoids in relation to function. *FASEB J* 9, 1551–1558.
- Briviba, K.; Schnabele, K.; Rechkemmer, G.; Bub, A. (2004): Supplementa- tion of a diet low in carotenoids with tomato or carrot juice does not affect lipid peroxidation in plasma and feces of healthy men. *J Nutr* 134, 1081–1083.
- Bub, A.; Watzl, B.; Abrahamse, L.; Delincee, H.; Adam, S. & Wever, J. (2000): Moderate intervention with carotenoid-rich vegetable products reduces lipid peroxidation in men. *J Nutr* 130, 2200–2206.
- Bub, A.; Barth, S. W.; Watzl, B.; Briviba, K. & Rechkemmer, G. (2005): Araoxonase 1 Q192R (PON1-192) polymorphism is associated with reduced lipid peroxidation in healthy young men on a low- carotenoid diet supplemented with tomato juice. *Br J Nutr* 93, 291–297.
- Chen, L.; Stacewicz-Sapuntzakis, M.; Duncan, C.; Sharifi, R.; Ghosh, L. & Van Breemen, R. (2001): Oxidative DNA damage in prostate cancer patients consuming tomato sauce-based entrees as a whole-food intervention. *J Natl Cancer Inst* 93, 1872–1879.
- Chopra, M.; O'Neill, M. E.; Keogh, N.; Wortley, G.; Southon, S. & Thurnham, D. I. (2000): Influence of increased fruit and vegetable intake on plasma and lipoprotein carotenoids and LDL oxidation in smokers and nonsmokers. *Clin Chem* 46, 1818–1829.
- Clinton, S. K.; Emenhiser, C.; Schwartz, S. J.; Bostwick, D. G.; Williams, A. W. & Moore, B. J. (1996): Cis–trans lycopene isomers, carotenoids, and retinol in the human prostate. *Cancer Epidemiol Biomarkers Prev* 5, 823–833.
- Cohen, L. (2002): A review of animal model studies of tomato carotenoids, lycopene and cancer chemoprevention. *Experimental Biology and Medicine*, 277: 864-868.
- Di Mascio, P.; Kaiser, S. & Sies, H. (1989): Lycopene as the most efficient biological carotenoid singlet oxygen quencher. *Arch Biochem Biophys* 274, 532–538.
- Diwadkar-Navsariwala, V.; Novotny, J. A.; Gustin, D. M.; Sosman, J. A.; Rodvold, K. A. & Crowell, J. A. (2003): A physiological pharmacokinetic model describing the disposition of lycopene in healthy men. *J Lipid Res* 44, 1927–1939.
- Fuhrman, B.; Elis, A. & Aviram, M. (1997): Hydpcholesterolemic effect of lycopene and β -carotene is related to suppression of cholesterol synthesis and augmentation of LDL receptor activity in macrophages-Biochemical and Biophysical Research Communications, 233: 658-662.
- Gartner, C.; Stahl, W. & Sies, H. (1997): Lycopene is more bioavailable from tomato paste than from fresh tomatoes. *Am J Clin Nutr* 66, 116–122.
- Giovannucci, E. (2002): A review of epidemiologic studies of tomatoes, lycopene and prostate cancer. *Experimental Biology and Medicine*, 227: 852-859.
- Hadley, C. W.; Clinton, S. K. & Schwartz, S. J. (2003): The consumption of processed tomato products enhances plasma lycopene concentrations in association with reduced lipoprotein sensitivity to oxidative damage. *J Nutr* 133, 727–732.

- Hantz, H. L.; Young, L. F.; Martin, K. R. (2005): Physiologically attainable concentrations of lycopene induce mitochondrial apoptosis in LNCaP human prostate cancer cells. *Exp Biol Med* 230, 171–179.
- Hininger, I. A.; Meyer-Wenger, A.; Moser, U.; Wright, A.; Southon, S. & Thurnham, D. (2001): No significant effects of lutein, lycopene or b-carotene supplementation on biological markers of oxidative stress and LDL oxidizability in healthy adult subjects. *J Am Coll Nutr* 20, 232–238.
- Holloway, D. E.; Yang, M.; Paganga, G.; Rice-Evans, C. A. & Bramley, P. M. (2000): Isomerization of dietary lycopene during assimilation and transport in plasma. *Free Radical Res* 32, 93–102.
- Hoppe, P. P.; Kramer, K.; Van den Berg, H.; Steenge, G. & Vliet, T. (2003): Synthetic and tomato-based lycopene have identical bioavailability in humans. *Eur J Nutr* 42, 272–278.
- Hwang, E. S. & Bowen, P. E. (2005): Effects of lycopene and tomato paste extracts on DNA and lipid oxidation in LNCaP human prostate cancer cells. *Biofactors* 23, 97–105.
- Jonker, D.; Kuper, C.; Fraile, N.; Estrella, A. & Otero, C. (2003): Ninety-day oral toxicity study of lycopene from *Blakeslea trispora* in rats. *Regul Toxicol Pharmacology*, 37: 396–406.
- Kim, Y.; Park, Y.; Lee, K.; Jeon, S.; Gregor, R. & Choi, S. (2012): Dose dependent effects of lycopene enriched tomato wino on liver and adipose tissue in high fat diet fed rats. *Food Chemistry*, 130: 42–48.
- Kiokias, S. & Gordon, M. H. (2003): Dietary supplementation with a natural carotenoid mixture decreases oxidative stress. *Eur J Clin. Nutr* 57, 1135–1140.
- Klipstein-Grobusch, K.; Launer, L.; Geleijnse, J.; Boeing, H.; Hofman, A. & Wtteman, J. (2000): Serum carotenoids and atherosclerosis. The Rotterdam study. *Atherosclerosis*, 148: 49–56.
- Khachik, F.; Carvalho, L.; Bernstein, P.S; Muir, G.; Zhao, D. & Katz, N. (2002): Chemistry, distribution and metabolism of tomato carotenoids and their impact on human health. *Experimental Biology and Medicine*, 227: 845–851.
- Kohlmeir, L.; Kark, J.; Gomez-Garcia, E.; Martin, B.; Steck, S. & Kardinaal, A. (1997): Lycopene and myocardial infraction risk in the EURAMIC study. *American Journal of Epidemiology*, 146: 618–626.
- Kucuk, O.; Sarkar, F. H.; Sakr, W.; Djurie, Z.; Pollak, M. N. & Khachik, F. (2001): Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy. *Cancer Epidemiol Biomarkers Prev* 10, 861–868.
- Lee, A.; Thurnham, D. & Chopra, M. (2000): Consumption of tomato products with olive oil but not sunflower oil increases the antioxidant activity of plasma. *Free Radical Biol Med* 29, 1051–1055.
- Levin, G.; Yeshurun, M. & Mokady, S. (1997): In vivo antiperoxidative effect of 9-cis b-carotene compared with that of the all-trans isomer. *Nutr Cancer* 27, 293–297.
- Libby, P. (2006): Inflammation and cardiovascular disease mechanisms. *Am J Clin Nutr* 83, 456S–460S.
- Liu, C.; Russell, R. M. & Wang, X. D. (2006): Lycopene supplementation prevents smoke-induced changes in p53, p53 phosphorylation, cell proliferation, and apoptosis in the gastric mucosa of ferrets. *J Nutr* 136, 106–111.

- Lorenz, M.; Fechner, M.; Kalkowski, J.; Frohlich, K.; Trautman, A.; Bohm, V.; Liebisch, G.; Lehneis, S.; Schmitz, G.; Ludwing, A.; Baumann, G.; Stangl, K. & Stangle, V. (2012): Effects of lycopene on the initial state of atherosclerosis in New Zealand white rabbits. *PLoS one* 7: 1-8.
- Livny, O.; Kaplan, I.; Reifen, R.; Polak, S.; Madar, Z. & Schwartz, B. (2002): Lycopene inhibits proliferation and enhances gap-junctional communication of KB-1 human oral tumor cells. *Journal of Nutrition*, 132: 3754-3759.
- Nahum, A.; Hirsch, K. & Danilenko, M. (2000): Lycopene inhibition of cell cycle progression in breast and endometrial cancer cells is associated with reduction in cyclin D levels and retention of P 27 in the cyclin E- cdk 2 complexes. *Oncogene*, 26: 3428-3436.
- Omoni, O. & Aluko, R. (2005): The anticarcinogenic and antiatherogenic effects of lycopene: a review. *Trends in Food Science & Technology*, 16: 344-350.
- Parthasarathy, S. (1998): Mechanisms by which dietary antioxidants may prevent cardiovascular diseases. *Journal of Medicinal Food*, 1: 45-51.
- Paster, M.; Fander, H.; Boscoboinik, D. & Azzi, A. (1998): Lycopene in association with α -tocopherol inhibits at physiological concentrations proliferation of prostate carcinoma cells. *Biochemistry Biophysics Research communication*, 35: 582-585.
- Obermuller-Jevic, U. C.; Olano-Martin, E.; Corbacho, A. M.; Eiserich, J. P. Van der Vliet. A. & Valacchi, G. (2003): Lycopene inhibits the growth of normal human prostate epithelial cells in vitro. *J Nutr* 133, 3356–3360.
- Pool-Zobel, B. L.; Bub, A.; Muller, H.; Wollowski, I. & Rechkemmer, G. (1997): Consumption of vegetables reduces genetic damage in humans: first result of a human intervention trial with carotenoid-rich foods. *Carcinogenesis* 18, 1847–1850.
- Porrini, M.; Riso, P. & Testolin, G. (1998): Absorption of lycopene from single or daily portions of raw and processed tomato. *Br J Nutr* 80, 353–361.
- Porrini, M. & Riso, P. (2000): Lymphocyte lycopene concentration and DNA protection from oxidative damage is increased in women after a short period of tomato consumption 130, 189–192.
- Porrini, M.; Riso, P. & Oriani, G. (2002): Spinach and tomato consumption increases lymphocyte DNA resistance to oxidative stress but this is not related to cell carotenoid concentrations. *Eur J Nutr* 41, 95-100.
- Porrini, M.; Riso, P.; Brusamolino, A.; Berti, C.; Guarnieri, S. & Visioli, F. (2005): Daily intake of a formulated tomato drink affects carotenoid plasma and lymphocyte concentrations and improves cellular antioxidant protection. *Br J Nutr* 93, 93–99.
- Rao, A. V. & Shen, H. (2002): Effect of low dose lycopene intake on lycopene bioavailability and oxidative stress. *Nutr Res* 22, 1125-1131.
- Rao, G.; Guns, E. & Rao, A. (2003): Lycopene: Its role in human health and disease. *Agro Food Industry In Tech*, 8: 25-30.
- Rao, A. V. (2004): Processed tomato products as a source of dietary lycopene: bioavailability and antioxidant properties. *Can J Diet Pract Res* 65, 161–165.
- Reboul, E. Borel, P.; Mikail, C.; Abou, L.; Charbonnier, M. & Caris-Veyrat. C. (2005): Enrichment of tomato paste with 6% tomato peel increases lycopene and b-carotene bioavailability in men. *J Nutr* 135, 790–794.

- Re, R.; Fraser P. D.; Long M, Bramley P. M. & Rice-Evans C. (2001): Isomerization of lycopene in the gastric milieu. *Biochem Biophys Res Commun* 281, 576–581.
- Richelle, M.; Bortlik, K.; Liardet, S.; Hager, C.; Lambelet, P. & Baur, M. (2002): A food-based formulation provides lycopene with the same bioavailability to humans as that from tomato paste. *J Nutr* 132, 404–408.
- Riso, P.; Pinder, A.; Santangelo, A. & Porrini, M. (1999): Does tomato consumption effectively increase the resistance of lymphocyte DNA to oxidative damage? *Am J Clin Nutr* 69, 712–718.
- Riso, P.; Visioli, F.; Erba, D.; Testolin, G. & Porrini, M. (2004): Lycopene and vitamin C concentrations increased in plasma and lymphocytes after tomato intake. Effects on cellular antioxidant protection. *Eur J Clin Nutr* 58, 1350–1358.
- Rissanen, T.; Voutilainen, S.; Nyyssonen, K.; Salonen. & Salonen J. T. (2000): Low plasma lycopene concentrations is associated with increased intima-media thickness of the carotid artery wall. *Arteriosclerosis, Thrombosis and Vascular Biology*, 20: 677-2681.
- Rissanen, T.; Voutilainen, S.; Nyyssonen, K.; Salonen, J. Kaplan, G. & Salonen, J. (2003): Serum lycopene concentration and carotid atherosclerosis: the Kuopio Ischemic Heart Disease Risk Factor Study. *Am J Clin Nutr* 77, 133–138.
- Sesson, H. D.; Liu, S.; Gaziano, M. & Buring, J. (2003): Dietary lycopene, tomato-based food products and cardiovascular disease in women. *Journal of Nutrition*, 133: 2336-341.
- Shi, J. (2000): Lycopene in tomatoes: Chemical and physical properties affected by food processing. *Critical Reviews In Food Science and Nutrition*, 40: 1-42.
- Stahl, W.; Junghans, A.; Boer, B.; Driomina, E.; Briviba, K. & Sies, H. (1998): Carotenoid mixtures protect multilamellar liposomes against oxidative damage: synergistic effects of lycopene and lutein. *FEBS Lett.* 42: 305-308.
- Unlu, N. Z.; Bohn, T.; Clinton, S. K. & Schwartz, S. J. (2005): Carotenoid absorption from salad and salsa by humans is enhanced by the addition of avocado or avocado oil. *J Nutr* 135, 431–436.
- Upritchard, J. E.; Sutherland, W. H. F.; Mann, J. I. (2000): Effect of supplementation with tomato juice, vitamin E, and vitamin C on LDL oxidation and products of inflammatory activity in Type 2 diabetes. *Diabetes Care* 23, 733–738.
- Visioli, F.; Riso, P.; Grande, S.; Gall, C. & Porrini, M. (2003): Protective activity of tomato products on in vivo markers of lipid oxidation. *Eur J Nutr* 42, 201–206.
- Willis, M. S. & Wiams, F. H. (2003): The role of nutrition in preventing prostate cancer: a review of the proposed mechanisms of action of various dietary substances. *Clinica Chimica Acta*, 330:57-83.
- Wu, K.; Schwaz, S. J.; Platz, A.; Clinton, S.; Erdman, J. & Ferruzzi, M. (2003): Variations in plasma lycopene and specific isomers over time in a cohort of US men. *Journal of Nutrition*, 133: 1930-1936.
- Zhao, X.; Aldini, G.; Johnson, E. J.; Rasmussen, H. Kraemer, K. & Woolf, H. (2006): Modification of lymphocyte DNA damage by carotenoid supplementation in postmenopausal women. *Am J Clin Nutr* 83, 163–169.